{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:33:34Z","timestamp":1792683214460,"version":"4.5.0"},"reference-count":82,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The standard of care for advanced or metastatic urothelial carcinoma (mUC) was historically identified with platinum-based chemotherapy. Thanks to the advances in biological and genetic knowledge and technologies, new therapeutic agents have emerged in this setting recently: the immune checkpoint inhibitors and the fibroblast growth factor receptor inhibitors as the target therapy for patients harboring alterations in the fibroblast growth factor receptor (FGFR) pathway. However, chasing a tumor\u2019s tendency to recur and progress, a new class of agents has more recently entered the scene, with promising results. Antibody\u2013drug conjugates (ADCs) are in fact the latest addition, with enfortumab vedotin being the first to receive accelerated approval by the U.S. Food and Drug Administration in December 2019, followed by sacituzumab govitecan. Many other ADCs are still under investigation. ADCs undoubtedly represent the new frontier, with the potential of transforming the management of mUC treatment in the future. Therefore, we reviewed the landscape of mUC treatment options, giving an insight into the molecular basis and mechanisms, and evaluating new therapeutic strategies in the perspective of more and more personalized treatments.<\/jats:p>","DOI":"10.3390\/ijms25179696","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:59:08Z","timestamp":1725861548000},"page":"9696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives"],"prefix":"10.3390","volume":"25","author":[{"given":"Elena","family":"Tonni","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oltrecolli","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirola","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Tchawa","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Roccabruna","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3060-6169","authenticated-orcid":false,"given":"Elisa","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Matranga","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-4536","authenticated-orcid":false,"given":"Claudia","family":"Piombino","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pipitone","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Baldessari","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bacchelli","sequence":"additional","affiliation":[{"name":"Clinical Trials Office, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1503","authenticated-orcid":false,"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"},{"name":"Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"ref_1","unstructured":"(2024, July 23). Bladder Cancer Statistics|World Cancer Research Fund International. Available online: https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics."},{"key":"ref_2","first-page":"e1","article-title":"Real-World Treatment Patterns and Clinical Outcomes among Patients with Advanced Urothelial Carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"18","author":"Hansen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of Patients with Metastatic Urothelial Cancer \u201cUnfit\u201d for Cisplatin-Based Chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in Bladder Cancer Biology and Therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab First-Line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-023-01475-9","article-title":"Novel ADCs and Combination Therapy in Urothelial Carcinoma: Latest Updates from the 2023 ASCO-GU Cancers Symposium","volume":"16","author":"Yu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Roviello, G., Santoni, M., Sonpavde, G.P., and Catalano, M. (Nat. Rev. Urol., 2024). The Evolving Treatment Landscape of Metastatic Urothelial Cancer, Nat. Rev. Urol., online ahead of print.","DOI":"10.1038\/s41585-024-00872-0"},{"key":"ref_12","unstructured":"Masson, E. (2024, August 26). Anticorps Monoclonaux Conjugu\u00e9s et Bisp\u00e9cifiques en Canc\u00e9rologie\u2014Compte Rendu de la Journ\u00e9e de Saint Louis 2022. Available online: https:\/\/www.em-consulte.com\/article\/1623743\/anticorps-monoclonaux-conjugues-et-bispecifiques-e."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An Update on Antibody-Drug Conjugates in Urothelial Carcinoma: State of the Art Strategies and What Comes Next","volume":"90","author":"Chapman","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-Drug Conjugates for Urothelial Carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOU.0000000000001177","article-title":"Advances in Preclinical Assessment of Therapeutic Targets for Bladder Cancer Precision Medicine","volume":"34","author":"Herek","year":"2024","journal-title":"Curr. Opin. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Cancer Genome Atlas Research Network Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ydbio.2005.09.011","article-title":"Functions and Regulations of Fibroblast Growth Factor Signaling during Embryonic Development","volume":"287","author":"Thisse","year":"2005","journal-title":"Dev. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pezzicoli, G., Ciciriello, F., Musci, V., Minei, S., Biasi, A., Ragno, A., Cafforio, P., and Rizzo, M. (2024). Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma. Medicina, 60.","DOI":"10.3390\/medicina60040585"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 Protein Expression and Its Relationship to Mutation Status and Prognostic Variables in Bladder Cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in Bladder Cancer: Treatment Landscape and Future Challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_22","first-page":"1","article-title":"Enrichment of FGFR3-TACC3 Fusions in Patients with Bladder Cancer Who Are Young, Asian, or Have Never Smoked","volume":"2","author":"Nassar","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced Urothelial Carcinoma: Next-Generation Sequencing Reveals Diverse Genomic Alterations and Targets of Therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2559.2011.03856.x","article-title":"Activation of the PI3K\/Akt\/mTOR Pathway Correlates with Tumour Progression and Reduced Survival in Patients with Urothelial Carcinoma of the Urinary Bladder","volume":"58","author":"Sun","year":"2011","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Thomas, J., and Sonpavde, G. (2022). Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers, 14.","DOI":"10.3390\/cancers14071795"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iqbal, N., and Iqbal, N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int., 2014.","DOI":"10.1155\/2014\/852748"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary Analysis from DS8201-A-U105: A Phase 1b, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (T-DXd) with Nivolumab (Nivo) in Patients (Pts) with HER2-Expressing Urothelial Carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2022.40.16_suppl.4520","article-title":"RC48-ADC for Metastatic Urothelial Carcinoma with HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials","volume":"40","author":"Sheng","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A.G., and Slaby, O. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101618"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive Genomic Profiling of Upper-Tract and Bladder Urothelial Carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2023.41.16_suppl.4570","article-title":"Mismatch Repair Deficiency and Microsatellite Instability-High in Urothelial Carcinoma: A Systematic Review and Meta-Analysis","volume":"41","author":"Chandran","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0092-8674(00)80051-3","article-title":"Structural Basis for FGF Receptor Dimerization and Activation","volume":"98","author":"Plotnikov","year":"1999","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor Signaling Pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","article-title":"Precision Medicine in Cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1758835919890285","DOI":"10.1177\/1758835919890285","article-title":"Targeted Therapies for Advanced Bladder Cancer: New Strategies with FGFR Inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR Study: Results of Erdafitinib (Erda) versus Chemotherapy (Chemo) in Patients (Pts) with Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Receptor Alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs. ERDA plus Cetrelimab (ERDA+CET) for Patients (Pts) with Metastatic Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): Final Results from the Phase 2 Norse Study","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/acph-2024-0005","article-title":"A Comprehensive Overview of Selective and Novel Fibroblast Growth Factor Receptor Inhibitors as a Potential Anticancer Modality","volume":"74","author":"Jain","year":"2024","journal-title":"Acta Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma with FGF\/FGFR Genomic Alterations: Final Results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Benjamin, D.J., and Hsu, R. (2023). Treatment Approaches for FGFR-Altered Urothelial Carcinoma: Targeted Therapies and Immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1258388"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2217\/fon-2021-1629","article-title":"Targeting FGFR3 Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: The Phase III PROOF 302 Trial","volume":"18","author":"Pal","year":"2022","journal-title":"Future Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ungaro, A., Tucci, M., Audisio, A., Di Prima, L., Pisano, C., Turco, F., Delcuratolo, M.D., Di Maio, M., Scagliotti, G.V., and Buttigliero, C. (2022). Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells, 11.","DOI":"10.3390\/cells11050803"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1538-7445.AM2020-5581","article-title":"Abstract 5581: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urothelial Cancers","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_56","first-page":"1187","article-title":"Enfortumab Vedotin Induces Immunogenic Cell Death, Elicits Antitumor Immune Memory, and Shows Enhanced Preclinical Activity in Combination with Immune Checkpoint Inhibitors","volume":"10","author":"Olson","year":"2022","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A Phase I Study of Enfortumab Vedotin in Japanese Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab Vedotin after PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (EV-201): A Multicentre, Single-Arm, Phase 2 Trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 Long-Term Outcomes: 24-Month Findings from the Phase III Trial of Enfortumab Vedotin versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","unstructured":"U.S. Food & Drug Administration (2024, September 03). FDA Grants Accelerated Approval to Enfortumab Vedotin-Ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S1203","DOI":"10.1016\/j.annonc.2023.09.1014","article-title":"2365MO Study EV-103 Cohort L: Perioperative Treatment w\/ Enfortumab Vedotin (EV) Monotherapy in Cisplatin (Cis)-Ineligible Patients (Pts) w\/Muscle Invasive Bladder Cancer (MIBC)","volume":"34","author":"Sridhar","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1200\/JCO.2024.42.16_suppl.4564","article-title":"Study EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)\u20142-Year Event-Free Survival and Safety Data for Cohort H","volume":"42","author":"Hoimes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"TPS585","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS585","article-title":"Phase 3 KEYNOTE-905\/EV-303: Perioperative Pembrolizumab (Pembro) or Pembro + Enfortumab Vedotin (EV) for Muscle-Invasive Bladder Cancer (MIBC)","volume":"41","author":"Necchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","article-title":"KEYNOTE-B15\/EV-304: Randomized Phase 3 Study of Perioperative Enfortumab Vedotin plus Pembrolizumab versus Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)","volume":"39","author":"Hoimes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 Expression Contributes to Tumor Pathogenesis by Activating the ERK MAPK Pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in Upper Tract Urothelial Carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-Drug Conjugates Targeting TROP-2 and Incorporating SN-38: A Case Study of Anti-TROP-2 Sacituzumab Govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"TPS581","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS581","article-title":"TROPHY-U-01 Cohort 4: Sacituzumab Govitecan (SG) in Combination with Cisplatin (Cis) in Platinum (PLT)-Na\u00efve Patients (Pts) with Metastatic Urothelial Cancer (mUC)","volume":"40","author":"Tagawa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"TPS498","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS498","article-title":"TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic or Locally Advanced Unresectable Urothelial Cancer That Has Progressed after Platinum and Checkpoint Inhibitor Therapy","volume":"39","author":"Grivas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_74","first-page":"e21200012","article-title":"Advances in HER2-Targeted Treatment for Advanced\/Metastatic Urothelial Carcinoma","volume":"10","author":"Qu","year":"2023","journal-title":"Bladder"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"17562872241249073","DOI":"10.1177\/17562872241249073","article-title":"Systematic Review of Recent Advancements in Antibody-Drug and Bicycle Toxin Conjugates for the Treatment of Urothelial Cancer","volume":"16","author":"Domb","year":"2024","journal-title":"Ther. Adv. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Shih, C.-H., Lin, Y.-H., Luo, H.-L., and Sung, W.-W. (2024). Antibody-Drug Conjugates Targeting HER2 for the Treatment of Urothelial Carcinoma: Potential Therapies for HER2-Positive Urothelial Carcinoma. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1326296"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II Study (KAMELEON) of Single-Agent T-DM1 in Patients with HER2-Positive Advanced Urothelial Bladder Cancer or Pancreatic Cancer\/Cholangiocarcinoma","volume":"12","author":"Lolkema","year":"2023","journal-title":"Cancer Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab Deruxtecan in Patients with Solid Tumours Harbouring Specific Activating HER2 Mutations (DESTINY-PanTumor01): An International, Phase 2 Study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"TPS594","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594","article-title":"Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin with or without Pembrolizumab in Patients with HER2-Expressing Urothelial Carcinoma (RC48G001)","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2022.40.16_suppl.4519","article-title":"A Phase II Study of RC48-ADC in HER2-Negative Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:50:12Z","timestamp":1760111412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":82,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179696"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179696","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]}}}